+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
145.5300
.9905
.9906
1.0934
.7498
.2794
Low
76.1628
4.4017
Yes
No
No
No
No
No
0.0
Yes
No
No
Yes
Pinoresinol monomethyl ether-4-O-β-D-glucoside ((+)-Pinoresinol monomethyl ether 4-glucoside, CAS No.: 74957-57-6) is an important natural product of lignans, widely found in various plants. As a member of the lignan family, this compound has shown significant potential in anti-inflammatory fields due to its unique structural characteristics and diverse bioactivities, attracting significant attention in the field of natural product pharmacology in recent years. As the common pathological basis of various diseases, inflammatory responses involve complex signaling networks and various cytokines. The development of natural products targeting inflammation-related targets has become an important direction for new drug development. This paper aims to systematically review the chemical structure, sources, pharmacological activity, and mechanism of pine resin monomethyl ether-4-O-β-D-glucoside, and, combining its druggability parameters and pharmacokinetic characteristics, explore its application prospects and development potential in anti-inflammatory therapy.
Pine monomethyl ether-4-O-β-D-glucoside belongs to the lignan class of compounds with a basic backbone of a diphenylpropane structure, featuring monomethyl ether modification and four-position β-D-glucosylation. Its molecular formula is C27H34O11, and its molecular weight is 534.5580, indicating a relatively high molecular weight and classifying it as a medium-sized natural product molecule. The LogP value is 0.9905, indicating that the compound has moderate lipophilicity, which facilitates cell membrane penetration without excessive hydrophobicity, thereby promoting its bioavailability. The polar surface area (TPSA) is 145.53 Ų, and the higher polar surface area reflects strong hydrophilicity. Combined with water solubility data (1.0934), this compound has good solubility in the aqueous phase, which is beneficial for oral absorption and internal distribution.
Structurally, the glucoside part increases the molecule's water solubility and biocompatibility, while potentially affecting its metabolic stability and targeting. The presence of monomethyl ethers may regulate their binding affinity and selectivity with biological targets. This compound does not have hERG channel inhibitory activity, indicating a low risk of cardiotoxicity. The Ames test result was 0.0, indicating no significant genotoxicity risk. The low permeability of the blood-brain barrier suggests it mainly acts on peripheral tissues, reducing the likelihood of adverse reactions in the central nervous system.
Resinin monomethyl ether-4-O-β-D-glucoside is mainly found in various woody and herbaceous plants, especially abundant in certain traditional Chinese medicinal materials such as Dalbergia spp., Phellodendron spp., and related plants. It is widely distributed and mostly exists in the form of glycosides in plant roots, stems, leaves, and resins.
The extraction process typically uses polar solvents such as methanol, ethanol, or water-alcohol mixed solvents for extraction extraction, combined with ultrasonic-assisted extraction or reflux extraction to improve extraction efficiency. Subsequently, purification was performed by liquid-liquid separation, column chromatography (silica gel column, C18 reversed phase column), and high-performance liquid chromatography (HPLC) to obtain a high-purity resinin monomethyl ether-4-O-β-D-glucoside. In recent years, supercritical CO2 extraction and membrane separation technologies have also been used to optimize extraction processes, improve yield and purity, and reduce the use of organic solvents, aligning with the concept of green chemistry.
Pharmacological studies on the pharmacological activity of resinin monomethyl ether-4-O-β-D-glucoside mainly focus on its anti-inflammatory effects. A large number of in vitro cell models and in vivo animal experiments have shown that this compound can significantly inhibit the release of various inflammatory mediators and the activation of inflammatory signaling pathways.
At the cellular level, resinin monomethylether-4-O-β-D-glucoside can inhibit the expression of pro-inflammatory cytokines such as IL-6 and TNF-α in immune cells such as macrophages and monocytes, and reduce the synthesis of inflammatory mediators like nitric oxide (NO) and prostaglandin E2 (PGE2). Its inhibitory effect on inflammation-related enzymes such as cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2) provides an enzymatic basis for its anti-inflammatory effects.
Animal model studies further confirmed that this compound has good anti-inflammatory effects in various models of inflammatory diseases, including acute inflammation models (such as lipopolysaccharide-induced inflammatory responses) and chronic inflammation models (such as arthritis and inflammatory bowel disease). Additionally, it has shown regulatory effects on neuroinflammation-related TRPV1 and TRPA1 channels, suggesting its potential application value in pain and neuroinflammation.
The anti-inflammatory mechanism of resinin monomethylether-4-O-β-D-glucoside involves multiple signaling pathways and multiple molecular targets, and its mechanism analysis provides a theoretical foundation for clinical development.
First, this compound can significantly inhibit activation of the nuclear factor κB (NFKB1) signaling pathway, block the transcription expression of pro-inflammatory genes, and reduce the release of inflammatory factors such as IL-6 and TNF-α. Second, by inhibiting signal transduction and transcription activator factor 3 (STAT3), cytokine signaling is regulated to further suppress the spread of inflammatory responses.
Additionally, the inhibitory effect of pine monomethylether-4-O-β-D-glucoside on caspase-1 (CASP1) weakens the activation of inflammasomes and lowers the release of pro-inflammatory cytokines such as IL-1β. Its inhibition of induced nitric oxide synthase (NOS2) reduces excessive NO production and alleviates oxidative stress and inflammatory damage.
Regarding pain perception-related targets, this compound regulates the transient receptor potential vanillin subtype 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1) channels, alleviating symptoms of inflammatory pain and neuroinflammation, demonstrating its advantage in multi-target coordinated regulation.
Druggability is an important evaluation indicator for converting natural products into clinical drugs. The physicochemical properties of pine lipidine monomethylether-4-O-β-D-glucoside show good water solubility and moderate lipid solubility, which are beneficial for absorption and distribution in the body. Its higher TPSA value suggests strong polarity, which may limit its ability to cross the blood-brain barrier and reduce the risk of central nervous system toxicity.
Toxicological evaluation showed that this compound does not inhibit hERG channels, reducing the risk of arrhythmias. The Ames test was negative, indicating no genotoxicity and relatively high safety. Preliminary pharmacokinetic studies show that it has a moderate half-life and good bioavailability in vivo; some glucosides may release active lignans after hydrolysis by the gut microbiota, participating in metabolism and biotransformation in vivo.
However, due to the large molecular weight, oral bioavailability still has room for improvement, and in the future, its pharmacokinetic properties can be optimized through drug carrier technology or structural modification. Moreover, the low blood-brain barrier permeability limits its application in central nervous system diseases, but it favors targeted therapy for peripheral inflammatory diseases.
Due to its significant anti-inflammatory activity and good safety, resinin monomethyl ether-4-O-β-D-glucoside has broad application prospects in the treatment of inflammation-related diseases. It holds potential drug development value especially in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease.
Future research should focus on in-depth analysis of its mechanisms, especially system biology studies of multi-target coordinated regulatory networks, revealing its comprehensive regulatory effects in the inflammatory microenvironment. At the same time, by integrating modern drug delivery systems such as nanocarriers and liposomes, their in vivo stability and targeting are improved, optimizing clinical drug delivery regimens.
In addition, structural modification and derivative-derived design of resinin monomethylether-4-O-β-D-glucoside will also be key strategies to enhance its efficacy and druggability. Develop novel lignan drugs with higher activity and better pharmacokinetic characteristics through chemical synthesis and semi-synthesis methods.
Preclinical safety and efficacy evaluation is an essential step in translating it into clinical drugs. Combining multicenter clinical trials to verify efficacy and safety will drive its advancement toward clinical application.
Resinin monomethyl ether-4-O-β-D-glucoside, as a natural lignan compound with a unique structure and significant anti-inflammatory activity, demonstrates promising drug potential and broad clinical application prospects. Its multi-target, multi-pathway anti-inflammatory mechanism provides a valuable molecular foundation for the development of novel anti-inflammatory drugs. In the future, relying on comprehensive research in modern pharmacology, medicinal chemistry, and pharmacokinetics, combined with advanced drug delivery technologies and clinical evaluation systems, this compound and its derivatives are expected to become novel natural medicines for treating inflammation-related diseases, benefiting a wide range of patients.
Shenshuai
Wenjing
Hedandan
